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According to the World Health Organization (WHO), approximately 1.7 million deaths per year 
are caused by tuberculosis infections. Furthermore, it has been predicted that, by 2050, 
antibacterial resistance will be the cause of approximately 10 million deaths annually if the issue 
is not tackled. As a result, novel approaches to treating broad-spectrum bacterial infections are 
of vital importance. During the course of our wider efforts to discover unique methods of 
targeting multidrug-resistant (MDR) pathogens, we identified a novel series of amide-linked 
pyrimido[4,5-b]indol-8-amine inhibitors of bacterial type II topoisomerases. Compounds from 
the series were highly potent against gram-positive bacteria and mycobacteria, with excellent 
potency being retained against a panel of relevant Mycobacterium tuberculosis drug-resistant 
clinical isolates. 
2018 Elsevier Ltd. All rights reserved. 
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Antibiotic resistance is rapidly becoming prevalent in both 
a clinical and a community setting. Alarmingly, it is predicted 
that failure to address this issue could lead to approximately 
10 million deaths per year by 2050.1 A recent report by the 
WHO identified tuberculosis (TB) as a global priority for 
research and development due to its status as the number one 
global infectious disease killer, causing 1.7 million deaths per 
year.2 A further 12 priority pathogens were identified, 
consisting of Acinetobacter baumannii, Pseudomonas 
aeruginosa, Enterobacteriaceae, Enterococcus faecium, 
Staphylococcus aureus, Helicobacter pylori, Campylobacter 
spp, Salmonellae, Neisseria gonorrhoeae, Streptococcus 
pneumoniae, Haemophilus influenzae and Shigella spp. 
Antibiotics such as fluoroquinolones have had great 
clinical success, however, bacteria have evolved resistance to 
entire classes of antibiotics. Overexpression of efflux pumps, 
target-specific mutations, modifications to the bacterial cell 
wall and the generation of drug-inactivating enzymes can all 
contribute to bacterial resistance.3 Consequently, research into 
chemical series’ with the ability to target drug-resistant 
bacteria are of utmost importance. One method of overcoming 
site-specific mutation resistance is to target alternative 
binding sites which are capable of inducing the same 
phenotypic response. 
DNA gyrase and topoisomerase IV are two examples of 
highly homologous bacterial type IIA topoisomerases which 
have the ability to break, reorganise and religate DNA 
strands.4 Without recourse to these enzymes, bacteria are not 
able to appropriately manipulate the topology of their DNA, 
resulting in eventual cellular death. Fluoroquinolones target 
the DNA binding site of topoisomerases in order to elicit their 
therapeutic effect, however, recent publications have focused 
on inhibition at an alternative site (the ATPase sites on 
GyrB/ParE on DNA gyrase/topoisomerase IV respectively) in 
order to circumvent resistance mechanisms. In the 60 years 
since the first GyrB/ParE inhibitor, novobiocin 1 (Figure 1), 
was discovered, many chemical series have been developed 
through fragment-based screening, high-throughput screening 
and scaffold hopping.5-10 
Herein we describe the discovery and structure-activity 
relationship (SAR) of a novel series of amide-linked 
pyrimido[4,5-b]indol-8-amine inhibitors of bacterial type II 
topoisomerase, which were identified using computational  
 
Figure 1. Novobiocin 1 
analysis of published GyrB inhibitors and an antibacterial 
library screen. It was observed in many of the previously 
published crystal structures of GyrB that a flexible loop 
adjacent to the ATPase site was poorly ordered, and usually 
omitted from the deposited coordinates (green arrow, Figure 
2a). Due to the absence of the resolved loop in many 
structures, proposed interactions in this area have been poorly 
modelled computationally. However, when an X-ray crystal 
structure in which this loop was resolved (PDB: 3G7E, green) 
was overlayed with a range of inhibitors, an unexplored 
vector near Asp106 was revealed (blue arrow). It was 
postulated that establishing initial SAR along this vector 
could serve to both probe the computational model and allow 
elaboration of a novel inhibitor series. Investigation of the 
SAR in this way could afford improvements to a variety of 
PK properties, by highlighting a region of the scaffold from 
which further optimisation could progress. In combination 
with these structural studies, an in-house compound library 
screen identified hit compound 2aa (Figure 2b, Table 1), 
where the substituent probing the Asp106 vector is attached 
via a novel amide linker. This discovery prompted further 
investigation of the novel amide-linked pyrimido[4,5-b]indol-
8-amine scaffold as a means of challenging the SAR in this 
region. 
Utilising the previously reported intermediate 311 (Scheme 
1) allowed the synthesis of final compounds 2aa-2di to 
proceed efficiently via a reproducible, reliable route, from 
which a range of analogues could be generated. Disulfone 3 
was identified as an important intermediate, since several 
points of diversity could be explored from this compound. 
Substitution with a variety of 3-substituted pyrrolidines 
yielded compounds 4, with the relative structural 
configuration established through an observed Nuclear 
Overhauser effect between the pyrrolidine substituent and the 
pyrimidine core (Scheme 1). 
a) 
  
b) 
 
Figure 2. a) Proposed vector (blue arrow), from which the inhibitor could be expanded in the side-chain pocket, towards Asp106. Figure generated from 
overlaying structures of 3G7E,12 4K4O10 and 5D7C.13 The flexible loop of residues, which are omitted in all structures but present in 3G7E, is highlighted in 
green. The approximate space-fill surface for the majority of published inhibitors is shown in black. b) Hypothesised amide-linked pyrimido[4,5-b]indol-8-amine 
compounds that could utilise a previously underexplored vector (blue arrow). Both figures generated using Maestro Version 10.6.014.14 
 Scheme 1. Use of disulfone 3 to introduce structural diversity. Reagents and conditions: (i) substituted pyrrolidine, K2CO3, EtOH, 45 °C, 50 min, MW, 61 - 89% 
(ii) NaCN, DMF, 100 °C, 16 h, 60 - 89% (iii) Raney nickel, H2, EtOH, rt, 16 h, 68- 97% (iv) ArCOOH, EDCI, Et3N, DCM, rt, 16 h, 13 - 67% (v) HCl (4N in 
dioxane), MeOH, rt, 16 h, 14 - 99%. 
Aromatic nucleophilic substitution of 4 with sodium cyanide 
then afforded key intermediate 5 (Scheme 1), which could be 
elaborated through nitrile reduction, unmasking primary 
amines of the form 6. Amide coupling with an appropriate 
carboxylic acid followed by deprotection yielded amides of 
the form 2aa-2di (Table 1). The carboxylic acids were 
selected on the basis of their commercial availability and 
similarity to those previously reported in the literature.  
Final compounds 2aa-2di were tested against a panel of 
antibacterial strains (Table 1), including gram-positive 
pathogens (E. faecalis and S. aureus), gram-negative 
pathogens (E. coli) and mycobacteria (M. smegmatis and M. 
tuberculosis). 
Incorporation of an oxazole moiety at the amide (2ac and 
2ad), provided potency against M. smegmatis and M. 
tuberculosis (Table 1). Interestingly, a potency increase 
against gram-positive bacteria and mycobacteria was 
observed upon N,N-dimethylation of the 3-aminopyrrolidine, 
consistent with the hypothesised increase in permeability 
upon removal of the H-bond donating ability of the 
primary/secondary amine. Encouraged by the improved 
potency of the oxazole subseries, the SAR was further 
challenged through subsequent methylation of the oxazole 
ring. Oxazole methylation tended to increase the potency for a 
series, however, the position of optimal methylation was 
variable. Computational methods (See Computational 
Analysis section, below) were utilised to aid rationalisation of 
these results. In order to further profile the series, a selection 
of compounds were tested against a broader panel of gram-
positive and gram-negative bacteria, and assessment of their 
in vitro cytotoxicity was undertaken (Table 2). 
Representative compounds were found to partially retain 
activity against a broader spectrum of bacteria, with no toxic 
effects observed in a HepG2 mammalian cytotoxicity assay 
for the majority of the tested compounds. Importantly, 
examples from the series were found to be more potent 
against M. tuberculosis than novobiocin 1. Target engagement 
was confirmed by testing for the ability of the inhibitor to 
prevent DNA supercoiling, and through its capacity to inhibit 
ATP hydrolysis (Table 3). Inhibition of human topoisomerase 
II decatenation highlighted the high bacterial selectivity of the 
series (Table 3). 
As a result of the high potency against M. tuberculosis, 
representative compounds from our novel series were tested 
against a panel of bacterial strains bearing mechanisms that 
rendered them resistant to clinically utilised antibiotics. All 
the resistant strains used were derived from M. tuberculosis 
H37Rv, and carried resistance mechanisms as outlined in 
Table 4. 
Gratifyingly, the Redx Pharma series was observed to 
maintain potency against the tested resistant isolates, 
highlighting a benefit in the current series compared to the 
clinically-relevant compounds moxifloxacin, isoniazid, 
rifampicin and novobiocin. 
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Compound R1 R2 
MIC (µg/mL)a 
Ef Sa Ec Ms Mt 
Novobiocin 1 - - 4 (ref.15) 0.06 >64 1 4 (ref.16) 
8 a H 8 8 8 N.D. N.D. 
2aa a a 0.25 32 8 N.D. N.D. 
2ab a b 0.12 8 4 N.D. N.D. 
2ac a c 0.06 8 128 0.12 N.D. 
2ad a d 1 8 4 0.25 0.25 
2bc b c 0.25 16 16 0.5 0.12 
2bd b d 0.5 8 4 0.5 0.03 
2be b e 0.25 4 4 0.06 0.03 
2cd c d 0.015 0.5 0.25 0.06 0.06 
2ce c e 0.03 1 2 0.06 0.06 
2cf c f 0.015 1 1 0.002 N.D. 
2cg c g 0.12 0.25 0.5 0.06 0.03 
2ch c h 0.5 1 4 0.25 0.25 
2dd d d 0.12 4 4 0.06 0.03 
2de d e 0.5 8 8 0.03 0.015 
2df d f 0.25 8 4 0.12 0.015 
2di d i 1 8 32 0.06 N.D. 
aEf (E. faecalis ATCC 29212), Sa (S. aureus ATCC 29213), Ec (E. coli ATCC 25922), Ms (M. smegmatis ATCC 19420), Mt (M. 
tuberculosis H37Rv). N.D. (not determined). 
Table 1. In vitro antibacterial activity of novobiocin 1 and amide-linked pyrimido[4,5-b]indol-8-amine inhibitors. 
Compound 
MIC (µg/mL)a 
HepG2 (IC50, µg/mL)b 
Ab Pa Hi Se Sp 
Novobiocin 1 N.D. >64 (ref.15) 0.5 (ref.15) 0.06 (ref.15) 0.5 (ref.15) >32 
2ac 16 128 1 1 0.12 10.82 
2ad 8 32 1 1 1 >16 
2bd >64 >64 4 2 2 >32 
2cd 1 >64 4 0.12 0.12 >16 
aAb (A. baumannii NCTC 13420), Pa (P. aeruginosa ATCC 27853), Hi (H. influenzae ATCC 49247), Se (S. epidermidis ATCC 
12228), Sp (S. pneumoniae ATCC 49619) bHep G2 cells incubated for 24 h at 37 °C in 5% CO2 and viability determined using 
CellTiter-Glo® (Promega, WI, USA). N.D. (not determined). 
Table 2. Extended in vitro antibacterial activity and cytotoxicity of novobiocin 1 and a selected amide-linked pyrimido[4,5-b]indol-8-
amine inhibitors. 
 
 
 
 
Compound 
M. tuberculosis gyrase 
supercoiling inhibition 
(IC50, µM) 
M. tuberculosis gyrase 
ATPase inhibition  
(IC50, µM) 
Human topoisomerase II 
decatenation inhibition 
(% inhibition at 100 µM) 
Novobiocin 1 0.085 0.020 N.D. 
2ac 0.005 0.025 5.8% 
2ad 0.010 0.059 21.2% 
Table 3. Target engagement of novobiocin 1 and selected amide-linked pyrimido[4,5-b]indol-8-amine inhibitors. N.D. (not determined).
 
 
Compound Ms Mt 
MIC (µg/mL)a 
FQ-R1 
(GyrA D94N 
substitution) 
INH-R1  
(truncated at 155 
of KatG) 
RIF-R1  
(RpoB S522L 
substitution) 
Moxifloxacin (FQ) 0.03 N.D. 3.9 0.04 0.04 
Isoniazid (INH) 4 N.D. 0.05 >27 0.014 
Rifampicin (RIF) 16 N.D. 0.019 0.013 3.0 
Novobiocin 1 1 4 (ref.16) 7.35 6.7 13.5 
2ac 0.12 N.D. 0.014 0.013 0.012 
2ad 0.25 0.25 0.09 0.09 0.09 
aMs (M. smegmatis ATCC 19420), Mt (M. tuberculosis H37Rv), FQ-R1 (fluoroquinolone-resistant), INH-R1 (isoniazid-resistant), 
RIF-R1 (rifampicin-resistant). N.D. (not determined). Data collected in May 2015. 
Table 4. In vitro antibacterial activity of clinically used antibiotics and amide-linked pyrimido[4,5-b]indol-8-amine inhibitors against 
resistant isolates. 
 
 
 
 
 
 
Figure 3. 9ce, and 9cf were used for the computational analysis, as analogues of 2ce and 2cf respectively. 
COMPUTATIONAL ANALYSIS 
Compound 2cf, the result of 2-methylation of the oxazole 
in 2cd, was found to be 5-fold higher in potency against M. 
smegmatis compared to the undecorated analogue. Although it 
was hypothesised that the addition of the methyl group may 
result in improved permeability through increasing 
lipophilicity, computational simulations were used to 
determine if the potency increase was due to a specific 
interaction. Molecular dynamics calculations were performed 
using Desmond v2.317 (see Experimental section, below) on 
two hypothetical analogues relating to 2ce and 2cf (9ce and 
9cf, Figure 3). As the most structurally similar analogue with 
an X-ray crystal structure (PDB: 4K4O10) utilised a bicyclic 
amine in the amine pocket, this was kept consistent 
throughout the simulations to ensure differences in binding 
could be rationalised primarily through alterations to the 
heterocycle inhabiting the side-chain pocket. 
The simulation showed that the protein-ligand interactions 
were stable, and key interactions were consistent with those 
observed in the X-ray crystal structure of similar GyrB 
inhibitors, providing confidence in the computational method. 
The most important binding interactions were found to be 
hydrogen bonds between the three nitrogen atoms on the 
tricyclic core and Asp73 and its coordinated water. 
Furthermore, a strong association of the oxazole ring with 
Arg76 was concordant with a π-cation interaction, consistent 
with published observations.10 As the core of the molecule 
remained unchanged throughout the simulations, focus was 
placed on how the heterocyclic amide may effect binding. The 
resulting interaction maps for the oxazole substituents are 
shown in Figure 4, with relative interaction probabilities 
annotated alongside. For example, an interaction probability 
of 61% related to the interaction being observed to occur 
during 61% of the simulation. 
a) 
 
b) 
 
9ce 9cf 
Figure 4. Interaction maps for structures relating to a) 9ce and b) 9cf 
Similar residues were observed to be involved in each 
compound’s binding interactions near the amide substituent, 
however, the extent of the binding was variable. Arg136 
formed a hydrogen bond with the amide carbonyl in both 
simulations. However, in 9cf, this interaction seemed more 
stable, with a higher interaction probability (up to 94% 
compared to up to 49% in 9ce). This improved interaction in 
9cf was hypothesised to be a result of the oxazole-methyl 
group in 9cf causing a steric clash with Arg136 in the active 
site, discouraging binding (Figure 5a). Movement of the 
methyl group to the 2-position of the oxazole could alleviate 
this clash, decreasing the overall energy of the system, and 
contributing to an increase the potency of the ligand. 
a) 
 
 
   
b) 
 
Figure 5. a) Potential clash of Arg136 with 9ce, which would be alleviated in 
9cf b) MD frame of 9cf highlighting the possible water-mediated interaction 
made with Asp106. 
Interestingly, an additional potency driving interaction may be 
picked up by 9cf to Asp106, which resides on the flexible 
loop commonly omitted from the majority of deposited X-ray 
crystal structures. The nitrogen atom in the oxazole ring of 9cf 
may be in a more appropriate orientation to bind via a water-
mediated interaction to Asp106 (Figure 5b). The existence of 
this interaction may reflect the increase in M. smegmatis 
potency observed between compounds 2ce and 2cf. 
Furthermore, elaboration along the vector towards Asp106 
may provide additional potency-driving interactions to 
optimise the series.  
In summary, utilising computational analysis of previously 
published crystal structures of GyrB inhibitors in DNA gyrase 
allowed the development of the current antibacterial series, 
focussing on improving the activity and spectrum of 
susceptible bacteria. A combination of expanding into an 
identified area of the active site, and alteration of permeability 
through removal of H-bond donors, has successfully yielded 
antibacterial compounds with potent activity against gram-
positive bacteria and mycobacteria. Furthermore, the potential 
of the series has been exemplified through the ability of the 
compounds to maintain activity against a range of drug-
resistant M. tuberculosis clinical isolates. Subsequent 
alterations of the amide-linked heterocycles have 
demonstrated steric bulk can not only be tolerated in this area 
of the protein, but additional potency increasing interactions 
could be designed into the inhibitors through interaction with 
Asp106, which resides on the flexible loop. 
EXPERIMENTAL 
Molecular dynamics 
Protein structures were prepared using Maestro's Protein 
Preparation Wizard (PrepWizard), following the procedure 
outlined by Sastry et al.18 Unfortunately, the X-ray crystal 
structure of 4K4O10 (E. faecalis) was not complete, and the 
flexible loop of residues that resided near the pyrimidine 
substituent were omitted, resulting in the use of a complete 
crystal structure, 3G7E12 (E. coli), instead. The suitability of 
the proteins to be interchanged was assessed by determining 
that 68% of residues within the active site were identical. Of 
the non-identical residues, mutation was commonly observed 
to be a result of a small change (e.g VAL to ILE). Each 
mutated residue was assessed for its contribution to binding, 
resulting in 95% similarity of the active sites of 4K4O and 
3G7E, and could therefore used interchangeably during the 
computational studies. Furthermore, both sequences were 
seen to be highly similar to 3ZM7 (M. tuberculosis), allowing 
comparisons in binding to be drawn from simulations of 
3G7E. Each compound was docked using a knowledge-based 
alignment and the protein-ligand complex was solvated and 
simulated for 8 ns at a temperature of 300K using the 
OPLS_2005 force field19 in Desmond v2.3.17 The system 
trajectories were then analysed using Maestro v10.6.01414, 
monitoring how key interactions evolved over the course of 
the experiment. 
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Supporting information 
General remarks 
NMR spectra were obtained on a LC Bruker AV500 using a 5 mm QNP probe. Coupling constants are 
reported in Hz and refer to 3JH-H interactions unless otherwise stated. 
LCMS was carried out on a Waters Alliance ZQ MS using H2O and MeCN mobile phase with pH 
modification as detailed below. Wavelengths measured were 254 and 210 nm. 
LCMS Method (Basic pH) 
Column: YMC-Triart C18 50 × 2 mm, 5 µm. Flow rate: 0.8 mL/min. Injection volume: 5 μL.  
Mobile Phase      A            H2O 
   B            MeCN 
   C            50% H2O / 50% MeCN + 1.0% ammonia 
 
 
 
Pyrrolidines 
a 
 
b 
 
c 
 
d 
 
Amides 
a 
 
b 
 
c 
 
d 
 
e 
 
f 
 
g 
 
h 
 
i 
 
Compounds contained within the Supplementary Information section are, 
where appropriate, numbered by pyrrolidine then amide. i.e. where pyrrolidine 
a and amide b are used, the final compound title is 2ab. 
Table 2 
  
Time (min) A (%) B (%) C (%) 
0 95 0 5 
4 0 95 5 
4.4 0 95 5 
4.5 95 5 0 
4.5 STOP 
Table 1 
Procedures 
General procedure for the synthesis of pyrrolidine substituted intermediates (4a-d) 
Following the general procedure below, the data are reported as a) mass of starting material; b) 
mass of pyrrolidine; c) mass of K2CO3; d) volume of ethanol; e) mass of product obtained. 
Following an adapted procedure of Bensen et al.,63 to a microwave vial was added tert-butyl N-[2,4-
bis(benzylsulfonyl)-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 3 (1.12 - 4.80 mmol, 
1 eq), corresponding pyrrolidine (either a) tert-butyl pyrrolidin-3-ylcarbamate, b) tert-butyl 
methyl(pyrrolidin-3-yl)carbamate, c) N,N-dimethylpyrrolidin-3-amine or d) tert-butyl (pyrrolidin-3-
ylmethyl)carbamate)  (1.46 - 5.28 mmol, 1.3 eq) and potassium carbonate (1.74 - 5.76 mmol, 1.5 eq) 
in EtOH. The mixture was heated in a Biotage Initiator microwave reactor at 45 °C for 50 min. The 
mixture was concentrated in vacuo and the resulting solid was dissolved in EtOAc, then washed with 
water then brine. The organic phase was concentrated in vacuo and purified by silica gel column 
chromatography (gradient = 0-100% EtOAc in petroleum ether (bp. 40-60)). The appropriate 
fractions were combined and concentrated in vacuo to give pyrrolidine-substituted intermediates 
4a-d in good yield. 
tert-butyl N-[2-benzylsulfonyl-4-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-9H-
pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (4a) 
Following the general procedure above: a) 3 g; b) 3-Boc-aminopyrrolidine, 984 mg; c) 996 mg; d) 30 
mL; e) 1.87 g. 
Yellow solid; yield 75%; LCMS: RT = 3.14 min, [M+H]+ 655.5; 1H NMR (400 MHz, CDCl3) δH 9.21 (s, 1H), 
7.62 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.3 Hz, 1H), 7.42 – 7.33 (m, 2H), 7.33 – 7.25 (m, 3H), 7.05 (dd, 3JH-F = 9.8 
Hz, 4JH-H = 2.3 Hz, 1H), 4.79 – 4.72 (m, 3H), 4.47 – 4.32 (m, 1H), 4.23 – 4.21 (m, 1H), 4.08 – 3.95 (m, 
2H), 3.84 (m, 1H), 3.34 (s, 3H), 2.37 – 2.24 (m, 1H), 2.12 – 2.05 (m, 1H), 1.49 (s, 18H). 
tert-butyl N-[1-[2-benzylsulfonyl-8-[tert-butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-
b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (4b) 
Following the general procedure above: a) 1.02 g; b) -(N-Boc-N-methylamino)pyrrolidine, 0.40 mL; c) 
344 mg; d) 5 mL; e) 700 mg. 
Off-white solid; yield 64%; LCMS: RT = 3.78 min, [M+H]+ 669.5; 1H NMR (500 MHz, CDCl3) δH 9.30 (s, 
1H), 7.61 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.3 Hz, 1H), 7.41 – 7.35 (m, 2H), 7.31 – 7.26 (m, 3H), 7.06 (dd, 3JH-F = 
9.8 Hz, 4JH-H = 2.3 Hz, 1H), 4.91 – 4.69 (m, 3H), 4.12 – 3.99 (m, 3H), 3.93 – 3.84 (m, 1H), 3.33 (s, 3H), 
2.88 (s, 3H), 2.29 – 2.10 (m, 2H), 1.49 (s, 18H). 
tert-butyl N-[2-benzylsulfonyl-4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-
b]indol-8-yl]-N-methyl-carbamate (4c) 
Following the general procedure above: a) 700 mg; b) N,N-dimethylpyrrolidin-3-amine, 0.16 mL; c) 
241 mg; d) 5 mL; e) 580 mg. 
Off-white solid; yield 89%; LCMS: RT = 3.34 min, [M+H]+ 583.2; 1H NMR (500 MHz, CDCl3) δH 9.02 (s, 
1H), 7.65 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.2 Hz, 1H), 7.42 – 7.36 (m, 2H), 7.32 – 7.28 (m, 3H), 7.04 (dd, 3JH-F 
= 9.8 Hz, 4JH-H = 2.2 Hz, 1H), 4.81 – 4.70 (m, 2H), 4.18 – 4.00 (m, 3H), 3.89 (dd, J = 10.3, 8.3 Hz, 1H), 
3.34 (s, 3H), 2.84 (p, J = 7.2, 6.6 Hz, 1H), 2.36 (s, 6H), 2.27 (s, 1H), 2.04 – 1.97 (m, 1H), 1.47 (s, 9H). 
tert-butyl N-[2-benzylsulfonyl-4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-
9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (4d) 
Following the general procedure above: a) 1.2 g; b) tert-butyl-(pyrrolidin-3-ylmethyl)carbamate, 0.42 
mL; c) 392 mg; d) 4 mL; e) 780 mg. 
Off-white solid; yield 61%; LCMS: RT = 3.66 min, [M+H]+ 669.2; 1H NMR (500 MHz, CDCl3) δH 9.54 (s, 
1H), 7.68 (d, 3JH-F = 9.8 Hz, 1H), 7.37 (s, 2H), 7.31 – 7.27 (m, 3H), 7.04 (d, 3JH-F = 9.8 Hz, 1H), 4.81 – 4.69 
(m, 2H), 4.10 – 3.98 (m, 3H), 3.78 – 3.72 (m, 1H), 3.33 (s, 3H), 3.31 – 3.20 (m, 2H), 2.57 – 2.53 (m, 
1H), 2.22 – 2.14 (m, 1H), 1.88 – 1.78 (m, 1H), 1.45 (s, 18H). 
  
General procedure for the synthesis of nitrile substituted intermediates (5a-d) 
Following the general procedure below, the data are reported as a) mass of starting material; b) 
mass of sodium cyanide; c) volume of DMF; d) mass of product obtained. 
A solution of sulfone intermediate 4a-d (1.00 – 2.86 mmol, 1 eq) and sodium cyanide (2.10 – 3.14 
mmol, 1.1-2.1 eq) in DMF was heated to 100 °C for 16 h. The reaction mixture was poured into water 
and extracted with EtOAc. The combined organics were extracted with water, brine, dried (MgSO4), 
filtered and concentrated in vacuo to give the crude product which was purified by silica gel column 
chromatography (gradient = 0-100% EtOAc in petroleum ether (bp. 40-60)). The appropriate 
fractions were combined and concentrated in vacuo to give the corresponding nitrile substituted 
intermediates 5a-d in good to excellent yield. 
tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-2-cyano-6-fluoro-9H-pyrimido[4,5-
b]indol-8-yl]-N-methyl-carbamate (5a) 
Following the general procedure above: a) tert-butyl N-[2-benzylsulfonyl-4-[3-(tert-
butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 
1.87 g; b) 150 mg; c) 27 mL; d) 1.29 g. 
White solid; yield 86%; LCMS: RT = 3.21 min, [M+H]+ 526.5; 1H NMR (400 MHz, CDCl3) δ 9.11 (s, 1H), 
7.61 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.3 Hz, 1H), 7.05 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.3 Hz, 1H), 4.88 – 4.59 (m, 
1H), 4.40 – 4.37 (m, 1H), 4.25 – 4.17 (m, 1H), 4.10 – 3.96 (m, 2H), 3.87 – 3.78 (m, 1H), 3.35 (s, 3H), 
2.38 – 2.25 (m, 1H), 2.13 – 2.00 (m, 1H), 1.46 (s, 18H). 
tert-butyl N-[1-[8-[tert-butoxycarbonyl(methyl)amino]-2-cyano-6-fluoro-9H-pyrimido[4,5-b]indol-
4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (5b) 
Following the general procedure above: a) tert-butyl N-[1-[2-benzylsulfonyl-8-[tert-
butoxycarbonyl(methyl)amino]-6-fluoro-9Hpyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-
carbamate 790 mg; b) 122 mg; c) 13 mL; d) 380 mg. 
Yellow solid; yield 60%; LCMS: RT = 3.84 min, [M+H]+ 540.6; 1H NMR (500 MHz, CDCl3) δH 9.35 (s, 1H), 
7.60 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.3 Hz, 1H), 7.06 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.3 Hz, 1H), 4.91 – 4.83 (s, 1H), 
4.09 – 3.95 (m, 3H), 3.92 – 3.84 (m, 1H), 3.35 (s, 3H), 2.89 (s, 3H), 2.29 – 2.11 (m, 2H), 1.49 (s, 18H). 
tert-butyl N-[2-cyano-4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-
N-methyl-carbamate (5c) 
Following the general procedure above: a) tert-butyl N-[2-benzylsulfonyl-4-[3-
(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9Hpyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 580 mg; 
b) 103 mg; c) 11 mL; d) 310 mg. 
Brown solid; yield 69%; LCMS: RT = 3.35 min, [M+H]+ 454.2; 1H NMR (500 MHz, CDCl3) δH 9.35 (s, 1H), 
7.64 (dd, 3JH-F = 9.9 Hz, 4JH-H = 2.2 Hz, 1H), 7.04 (dd, 3JH-F = 9.7 Hz, 4JH-H = 2.2 Hz, 1H), 4.14 – 3.97 (m, 
3H), 3.86 (dd, J = 10.4, 8.2 Hz, 1H), 3.35 (s, 3H), 2.87 – 2.78 (m, 1H), 2.37 (s, 6H), 2.29 – 2.25 (m, 1H), 
2.03 – 1.96 (m, 1H), 1.46 (s, 9H). 
 
 
tert-butyl N-[4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-2-cyano-6-fluoro-9H-
pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (5d) 
Following the general procedure above: a) tert-butyl N-[2-benzylsulfonyl-4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-
carbamate 780 mg; b) 114 mg; c) 15 mL; d) 560 mg. 
Yellow solid; yield 89%; LCMS: RT = 3.72 min, [M+H]+ 540.2, 484.1; 1H NMR (500 MHz, CDCl3) δH 9.08 
(s, 1H), 7.68 (d, 3JH-F = 9.8 Hz, 1H), 7.04 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.3 Hz, 1H), 4.83 – 4.73 (m, 1H), 4.10 
– 3.95 (m, 3H), 3.75 – 3.72 (m, 1H), 3.35 (s, 3H), 3.34 – 3.20 (m, 2H), 2.59 – 2.53 (m, 1H), 2.21 – 2.17 
(m, 1H), 1.84 – 1.80 (m, 1H), 1.46 (s, 18H).  
General procedure for the reduction of nitrile substituted intermediates (6a-d) 
Following the general procedure below, the data are reported as a) mass of starting material; b) 
volume of Raney nickel used; c) volume of ethanol; d) mass of product obtained. 
To a solution of corresponding nitrile intermediate 5a-d (0.10 – 1.04 mmol) in EtOH was added 
Raney nickel (aq. slurry). The flask was evacuated and purged with hydrogen 3 times then stirred at 
RT for 16 h under an atmosphere of hydrogen. The reaction mixture was filtered through celite, 
extracted with MeOH and concentrated in vacuo to furnish the corresponding amine product 6a-d in 
good yield. 
tert-butyl N-[1-[2-(aminomethyl)-8-[tert-butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-
b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (6a) 
Following the general procedure above: a) tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-
1-yl]-2-cyano-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 500 mg; b) 2 mL; c) 15 mL; 
d) 446 mg. 
Orange solid; yield 89%; LCMS: RT = 1.90 min, [M+H]+ 530.5. 
tert-butyl N-[1-[2-(aminomethyl)-8-[tert-butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-
b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (6b) 
Following the general procedure above: a) tert-butyl N-(4-benzylsulfonyl-2-cyano-6-fluoro-9H-
pyrimido[4,5-b]indol-8-yl)-N-methyl-carbamate 350 mg; b) 1 mL; c) 15 mL; d) 342 mg. 
Brown solid; yield 97%; LCMS: RT = 4.01 min, [M+H]+ 544.6.  
tert-butyl N-[2-(aminomethyl)-4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-
b]indol-8-yl]-N-methyl-carbamate (6c) 
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-
(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 310 mg; 
b) 2 mL; c) 15 mL; d) 214 mg. 
Orange solid; yield 68%; LCMS: RT = 2.58 min, [M+H]+ 458.2. 
tert-butyl N-[2-(aminomethyl)-4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-
9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (6d) 
Following the general procedure above: a) tert-butyl N-[4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-2-cyano-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-
methyl-carbamate 560 mg; b) 2 mL; c) 15 mL; d) 423 mg. 
Orange solid; yield 75%; LCMS: RT = 3.09 min, [M+H]+ 544.3. 
  
General procedure synthesis of Boc-protected final compounds (7) 
Following the general procedure below, the data are reported as a) mass of starting material; b) 
mass of acid; c) mass of EDCI; d) volume of DCM; e) volume of NEt3; f) mass of product obtained. 
To an ice cold solution of corresponding primary amine 6a-d (0.05 - 0.38 mmol, 1 eq), corresponding 
acid (0.06 - 0.48 mmol, 1.3 eq) and EDCI (0.05 - 0.49 mmol, 1.3 eq) in DCM was added NEt3 (0.06 - 
0.53 mmol, 1.4 eq) and the mixture was warmed to RT and stirred for 16 h. The reaction mixture was 
loaded directly onto a pre-equilibrated silica column and purified by silica gel column 
chromatography (gradient = 0-100% EtOAc in petroleum ether (bp. 40-60)). The appropriate 
fractions were combined and concentrated in vacuo to give the corresponding Boc-protected final 
compound 7. 
tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-2-[(pyridine-3-
carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7aa)  
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-(tert-
butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 
30 mg; b) Nicotinic acid 8 mg; c) 11 mg; d) 2 mL; e) 10 µL; f) 7 mg. 
Yellow oil; yield 18%; LCMS: RT = 3.08 min, [M+H]+ 625.3; 1H NMR (400 MHz, CD3OD) δH 9.03 (s, 1H), 
8.63 (s, 1H), 8.25 (s, 1H), 7.67 (s, 1H), 7.62 (dd,  3JH-F = 10.4 Hz, 4JH-H = 2.3 Hz, 1H), 6.93 (dd,  3JH-F = 
10.4 Hz, 4JH-H = 2.3 Hz, 1H), 4.52 (s, 2H), 4.18 – 3.93 (m, 3H), 3.92 – 3.81 (m, 1H), 3.74 – 3.67 (m, 1H), 
3.22 – 3.17 (m, 6H), 2.21 – 2.07 (m, 1H), 2.00 – 1.83 (m, 1H), 1.33 (s, 18H). 
tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-2-[(pyridazine-3-
carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7ab) 
Following the general procedure above: a) tert-butyl 2-[1-[2-(aminomethyl)-8-[tert-
butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]acetate 30 mg; 
b) pyridazine-3-carboxylic acid 7 mg; c) 9 mg; d) 2 mL; e) 8 µL; f) 4 mg. 
Yellow oil; yield 13%; LCMS: RT = 2.71 min, [M+H]+ 636.6. 
tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-2-[(oxazole-4-
carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7ac)  
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-(tert-
butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 
50 mg; b) oxazole-4-carboxylic acid 21 mg; c) 29 mg; d) 10 mL; e) 40 µL; f) 22 mg. 
Yellow oil; yield 45%; LCMS RT = 2.76 min, [M+H]+ 625.6; 1H NMR (400 MHz, CD3OD) δH 8.33 (d, 4JH-H 
= 1.0 Hz, 1H), 8.14 (d, 4JH-H = 1.0 Hz, 1H), 7.63 (dd,  3JH-F = 10.4 Hz, 4JH-H = 2.3 Hz, 1H), 6.94 (dd, 3JH-F = 
10.4 Hz, 4JH-H = 2.3 Hz, 1H), 4.52 (s, 2H), 4.15 – 3.96 (m, 3H), 3.91 – 3.87 (m, 1H), 3.77 – 3.74 (m, 1H), 
3.23 – 3.20 (m, 6H), 2.17 – 2.13 (m, 1H), 1.98 – 1.85 (m, 1H), 1.34 (s, 18H). 
 
 
tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-2-[(oxazole-5-
carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7ad)  
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-(tert-
butoxycarbonylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 
200 mg; b) oxazole-5-carboxylic acid 54 mg; c) 94 mg; d) 10 mL; e) 74 µL; f) 90 mg. 
Yellow oil; yield 55%; LCMS: RT = 2.56 min, [M+H]+ 625.6; 1H NMR (400 MHz, CD3OD) δH 8.25 (s, 1H), 
7.67 (s, 1H), 7.62 (dd, 3JH-F = 10.4 Hz, 4JH-H = 2.3 Hz, 1H), 6.93 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.3 Hz, 1H), 4.52 
(s, 2H), 4.13 – 3.93 (m, 3H), 3.92 – 3.81 (m, 2H), 3.74 – 3.67 (m, 1H), 3.19 (s, 3H), 2.21 – 2.07 (m, 1H), 
2.00 – 1.83 (m, 1H), 1.33 (s, 18H). 
tert-butyl N-[1-[8-[tert-butoxycarbonyl(methyl)amino]-6-fluoro-2-[(oxazole-4-
carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (7bc)  
Following the general procedure above: a) tert-butyl N-[1-[2-(aminomethyl)-8-[tert-
butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-
carbamate 48 mg; b) oxazole-4-carboxylic acid 12 mg; c) 18 mg; d) 3 mL; e) 12 µL; f) 30 mg. 
Orange solid; yield 53%; LCMS: RT = 3.49 min, [M+H]+ 639.7. 
tert-butyl N-[1-[8-[tert-butoxycarbonyl(methyl)amino]-6-fluoro-2-[(oxazole-5-
carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (7bd)  
Following the general procedure above: a) tert-butyl N-[1-[2-(aminomethyl)-8-[tert-
butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-
carbamate 52 mg; b) oxazole-5-carboxylic acid 13 mg; c) 18 mg; d) 4 mL; e) 18 µL; f) 32 mg. 
Red film; yield 52%; LCMS: RT = 3.27 min, [M+H]+ 639.7; 1H NMR (500 MHz, CDCl3) δH 9.36 (s, 1H), 
8.05 (s, 1H), 7.85 (s, 1H), 7.59 (dd,  3JH-F = 10.0 Hz, 4JH-H = 2.2 Hz, 1H), 7.02 – 6.95 (m, 1H), 4.89 – 4.71 
(m, 3H), 4.14 – 3.99 (m, 3H), 3.92 (t, J = 7.7 Hz, 1H), 3.35 (s, 3H), 2.90 (s, 3H), 2.29 – 2.12 (m, 2H), 
1.46 (s, 18H). 
tert-butyl N-[1-[8-[tert-butoxycarbonyl(methyl)amino]-6-fluoro-2-[[(4-methyloxazole-5-
carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-carbamate (7be)  
Following the general procedure above: a) tert-butyl N-[1-[2-(aminomethyl)-8-[tert-
butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-
carbamate 98 mg; b) 4-methyloxazole-5-carboxylic acid 34 mg; c) 37 mg; d) 6 mL; e) 28 µL; f) 21 mg. 
Orange solid; yield 18%; LCMS: RT = 3.37 min, [M+H]+ 653.3; 1H NMR (500 MHz, CDCl3) δH 9.12 (s, 
1H), 7.84 (s, 1H), 7.68 (t, J = 4.6 Hz, 1H), 7.58 (dd, 3JH-F = 10.0 Hz, 4JH-H = 2.2 Hz, 1H), 6.99 (dd, 3JH-F = 
10.0 Hz, 4JH-H = 2.2 Hz, 1H), 4.69 (d, J = 4.6 Hz, 2H), 4.14 – 3.99 (m, 3H), 3.91 (dd, J = 10.8, 7.9 Hz, 1H), 
3.34 (s, 3H), 2.89 (s, 3H), 2.56 (s, 3H), 2.28 – 2.11 (m, 3H), 1.46 (s, 18H). 
tert-butyl (4-(3-(dimethylamino)pyrrolidin-1-yl)-6-fluoro-2-((oxazole-5-carboxamido)methyl)-9H-
pyrimido[4,5-b]indol-8-yl)(methyl)carbamate (7cd) 
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-
(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 44 mg; 
b) oxazole-5-carboxylic acid 17 mg; c) 25 mg; d) 5 mL; e) 22 µL; f) 17 mg. 
Yellow film; yield 32%; LCMS: RT = 2.58 min, [M+H]+ 553.2; 1H NMR (500 MHz, CDCl3) δH 9.78 (s, 1H), 
8.01 (s, 1H), 7.97 (s, 1H), 7.93 (s, 1H), 7.62 (dd, 3JH-F = 10.2 Hz, 4JH-H = 2.4 Hz, 1H), 6.98 (dd, 3JH-F = 10.1 
Hz, 4JH-H = 2.4 Hz, 1H), 4.83 (s, 2H), 4.19 – 4.02 (m, 3H), 3.90 (t, J = 9.4 Hz, 1H), 3.35 (s, 3H), 2.84 (m, 
1H), 2.39 (s, 6H), 2.33 – 2.28 (m, 1H), 2.02 – 1.98 (m, 1H), 1.43 (s, 9H). 
tert-butyl N-[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-2-[[(4-methyloxazole-5-
carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7ce) 
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-
(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 42 mg; 
b) 4-methyloxazole-5-carboxylic acid 17 mg; c) 24 mg; d) 5 mL; e) 22 µL; f) 20 mg. 
Yellow film; yield 38%; LCMS: RT = 2.53 min, [M+H]+ 567.2; 1H NMR (500 MHz, CDCl3) δH 9.04 (s, 1H), 
7.84 (s, 1H), 7.74 (t, J = 4.6 Hz, 1H), 7.59 (dd, 3JH-F = 10.0 Hz, 4JH-H = 2.2 Hz, 1H), 6.97 (dd, 3JH-F = 9.8 Hz, 
4JH-H = 2.2 Hz, 1H), 4.68 (dd, J = 4.6, 2.4 Hz, 2H), 4.15 – 4.01 (m, 3H), 3.96 – 3.89 (m, 1H), 3.33 (s, 3H), 
2.85 (s, 1H), 2.56 (s, 3H), 2.43 (s, 6H), 2.35 – 2.29 (m, 1H), 2.04 – 1.99 (m, 1H), 1.44 (s, 9H). 
tert-butyl N-[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-2-[[(2-methyloxazole-5-
carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7cf)  
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-
(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 66 mg; 
b) 2-methyloxazole-5-carboxylic acid 27 mg; c) 38 mg; d) 7 mL; e) 28 µL; f) 42 mg. 
Yellow film; yield 51%; LCMS: RT = 2.64 min, [M+H]+ 567.2. 
tert-butyl N-[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-2-[(furan-2-carbonylamino)methyl]-9H-
pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7cg)  
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-
(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 50 mg; 
b) furan-2-carboxylic acid 18 mg; c) 27 mg; d) 5 mL; e) 21 µL; f) 28 mg. 
Yellow oil; yield 46%; LCMS: RT = 3.07 min, [M+H]+ 552.4; 1H NMR (500 MHz, CDCl3) δH 8.87 (s, 1H), 
7.91 – 7.87 (m, 1H), 7.62 (dd, 3JH-F = 10.1 Hz, 4JH-H = 2.3 Hz, 1H), 7.50 – 7.45 (m, 1H), 7.19 (d, J = 3.5 Hz, 
1H), 6.97 (dd, 3JH-F = 10.0 Hz, 4JH-H = 2.2 Hz, 1H), 6.53 (dd, J = 3.5, 1.6 Hz, 1H), 4.76 – 4.70 (m, 2H), 4.19 
– 4.03 (m, 3H), 3.91 – 3.83 (m, 1H), 3.34 (s, 3H), 2.87 – 2.77 (m, 1H), 2.38 (s, 6H), 2.32 – 2.28 (m, 1H), 
2.01 – 1.93 (m, 1H), 1.44 (s, 9H). 
tert-butyl N-[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-2-[(1H-pyrrolo[2,3-b]pyridine-6-
carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7ch) 
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-
(dimethylamino)pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 42 mg; 
b) 1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid 20 mg; c) 22 mg; d) 5 mL; e) 18 µL; f) 11 mg. 
Yellow film; yield 21%; LCMS: RT = 3.46 min, [M+H]+ 602.4 
 
 
 
tert-butyl N-[4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-2-[(oxazole-5-
carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7dd) 
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-
methylcarbamate 60 mg; b) oxazole-5-carboxylic acid 18 mg; c) 29 mg; d) 6 mL; e) 18 µL; f) 47 mg. 
Yellow oil; yield 67%; LCMS: RT = 3.09 min, [M+H]+ 639.2; 1H NMR (500 MHz, CDCl3) δH 9.15 (s, 1H), 
8.04 (s, 1H), 7.90 (s, 1H), 7.84 (s, 1H), 7.64 (d, 3JH-F = 9.8 Hz, 1H), 6.97 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.2 Hz, 
1H), 4.80 (s, 1H), 4.74 (d, J = 4.3 Hz, 2H), 4.10 – 3.97 (m, 2H), 3.76 (t, J = 9.1 Hz, 1H), 3.34 (s, 3H), 3.32 
– 3.20 (m, 2H), 2.63 – 2.49 (m, 1H), 2.25 – 2.14 (m, 1H), 1.89 – 1.78 (m, 1H), 1.44 (s, 18H). 
tert-butyl N-[4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-2-[[(4-
methyloxazole-5-carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 
(7de) 
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-
methylcarbamate 59 mg; b) 4-methyloxazole-5-carboxylic acid 20 mg; c) 28 mg; d) 6 mL; e) 19 µL; f) 
29 mg. 
Yellow oil; yield 36%; LCMS: RT = 3.24 min, [M+H]+ 653.3; 1H NMR (500 MHz, CDCl3) δH 8.65 (s, 1H), 
7.87 (s, 1H), 7.76 (s, 1H), 7.64 (d, 3JH-F = 9.8 Hz, 1H), 6.97 (dd, 3JH-F = 9.7 Hz, 4JH-H = 2.2 Hz, 1H), 4.79 – 
4.71 (m, 1H), 4.67 (d, J = 4.5 Hz, 2H), 4.09 – 4.01 (m, 2H), 3.75 (t, J = 9.2 Hz, 1H), 3.34 (s, 3H), 3.31 – 
3.22 (m, 2H), 2.57 (s, 3H), 2.61 – 2.49 (m, 1H), 2.24 – 2.15 (m, 1H), 1.87 – 1.77 (m, 1H), 1.44 (s, 18H). 
tert-butyl N-[4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-2-[[(2-
methyloxazole-5-carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate (7df)  
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-
methylcarbamate 59 mg; b) 2-methyloxazole-5-carboxylic acid 20 mg; c) 28 mg; d) 6 mL; e) 20 µL; f) 
24 mg. 
Yellow oil; yield 36%; LCMS: RT = 3.21 min, [M+H]+ 653.2; 1H NMR (500 MHz, CDCl3) δH 8.94 (s, 1H), 
7.74 (s, 1H), 7.64 (m, 2H), 7.01 – 6.92 (m, 1H), 4.81 (s, 1H), 4.71 (d, J = 4.4 Hz, 2H), 4.10 – 3.96 (m, 
2H), 3.77 (t, J = 9.1 Hz, 1H), 3.34 (s, 3H), 3.32 – 3.20 (m, 2H), 2.57 (s, 3H), 2.24 – 2.14 (m, 1H), 1.88 – 
1.79 (m, 1H), 1.70 – 1.61 (m, 1H), 1.44 (s, 18H). 
methyl 6-[[4-[3-[(tert-butoxycarbonylamino)methyl]pyrrolidin-1-yl]-8-[tert-
butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-b]indol-2-yl]methylcarbamoyl]pyridine-
2-carboxylate (7di) 
Following the general procedure above: a) tert-butyl N-[2-(aminomethyl)-4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-9H-pyrimido[4,5-b]indol-8-yl]-N-
methylcarbamate 55 mg; b) 6-methoxycarbonylpyridine-2-carboxylic acid 25 mg; c) 24 mg; d) 6 mL; 
e) 21 µL; f) 34 mg. 
Yellow oil; yield 52%; LCMS: RT = 3.59 mins, [M+H]+ 707.2; 1H NMR (500 MHz, CDCl3) δH 9.53 – 9.41 
(m, 1H), 8.94 (s, 1H), 8.49 (d, J = 7.7 Hz, 1H), 8.23 (dd, J = 7.6 Hz, 4JH-H = 1.2 Hz, 1H), 8.04 (t, J = 7.8 Hz, 
1H), 7.64 (d, 3JH-F = 9.6 Hz, 1H), 6.96 (dd, 3JH-F = 9.8 Hz, 4JH-H = 2.2 Hz, 1H), 5.37 – 5.28 (m, 1H), 4.83 (d, 
J = 4.6 Hz, 2H), 4.23 – 4.16 (m, 2H), 4.05 (s, 3H), 3.91 – 3.83 (m, 1H), 3.39 – 3.26 (m, 5H), 2.65 – 2.56 
(m, 1H), 2.24 – 2.17 (m, 1H), 1.91 – 1.82 (m, 1H), 1.46 – 1.39 (m, 18H). 
  
General procedure for Boc deprotection to yield final target compounds (2) 
Following the general procedure below, the data are reported as a) mass of starting material; b) 
volume of MeOH; c) volume of HCl (4M in dioxane); d) mass of product obtained as the HCl salt. 
To a solution of corresponding Boc-protected compound 7 (0.006 - 0.06 mmol) in MeOH was added 
HCl (4 M in dioxane) (0.01 – 6.30 mmol). The reaction mixture was stirred at RT for 30 min then 
concentrated in vacuo and azeotroped from MeOH twice to give the corresponding Boc-deprotected 
final compound 2 in good yield. 
2-(aminomethyl)-4-(3-aminopyrrolidin-1-yl)-6-fluoro-N-methyl-9H-pyrimido[4,5-b]indol-8-amine 
hydrochloride (8) 
Following the general procedure above: a) tert-butyl N-[1-[2-(aminomethyl)-8-[tert-
butoxycarbonyl(methyl)amino]-6-fluoro-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-
carbamate 15 mg; b) 1.5 mL; c) 1.5 mL; d) 6 mg. 
Yellow solid; yield 52%; LCMS: RT = 1.68 min, [M+H]+ 330.5. 
N-[[4-(3-aminopyrrolidin-1-yl)-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]pyridine-3-carboxamide hydrochloride (2aa) 
Following the general procedure above: a) tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-
1-yl]-6-fluoro-2-[(pyridine-3-carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-
carbamate 6 mg; b) 1.2 mL; c) 1.2 mL; d) 6 mg. 
Yellow solid; yield quant.; LCMS: RT = 1.72 min, [M+H]+ 435.4. 
N-[[4-(3-aminopyrrolidin-1-yl)-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]pyridazine-3-carboxamide hydrochloride (2ab) 
Following the general procedure above: a) tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-
1-yl]-6-fluoro-2-[(pyridazine-3-carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-
carbamate 4 mg; b) 1.2 mL; c) 1.2 mL; d) 3 mg. 
Yellow solid; yield 94%; LCMS: RT = 1.79 min, [M+H]+ 436.5. 
N-[[4-(3-aminopyrrolidin-1-yl)-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]oxazole-4-carboxamide hydrochloride (2ac) 
Following the general procedure above: a) tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-
1-yl]-6-fluoro-2-[(oxazole-4-carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-
carbamate 22 mg; b) 2.5 mL; c) 2.5 mL; d) 15 mg. 
Yellow solid; yield 98%; LCMS: RT = 1.80 min, [M+H]+ 426.5; 1H NMR (400 MHz, DMSO-d6) δH 12.50 
(s, 1H), 8.70 (d, 4JH-H = 1.0 Hz, 1H), 8.58 (d, 4JH-H = 1.0 Hz, 1H), 7.08 (dd, 3JH-F = 11.1 Hz, 4JH-H = 2.2 Hz, 
1H), 6.39 (dd, 3JH-F = 12.0 Hz, 4JH-H = 2.2 Hz, 1H), 4.62 (s, 2H), 4.29 – 4.17 (m, 2H), 4.08 – 3.95 (m, 3H), 
2.87 (s, 3H), 2.40 – 2.27 (m, 1H), 2.27 – 2.19 (m, 1H). 
 
N-[[4-(3-aminopyrrolidin-1-yl)-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]oxazole-5-carboxamide hydrochloride (2ad) 
Following the general procedure above: a) tert-butyl N-[4-[3-(tert-butoxycarbonylamino)pyrrolidin-
1-yl]-6-fluoro-2-[(oxazole-5-carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-
carbamate 90 mg; b) 2 mL; c) 4 mL; d) 60 mg. 
Yellow solid; yield 98%; LCMS: RT = 2.17 min, [M+H]+ 425.2; 1H NMR (400 MHz, DMSO-d6) δH 12.10 (s, 
1H), 9.12 (t, J = 6.0 Hz, 1H), 8.66 (s, 1H), 8.37 (s, 2H), 7.94 (s, 1H), 7.12 (dd, 3JH-F = 11.1 Hz, 4JH-H = 2.2 
Hz, 1H), 6.42 (dd, 3JH-F = 12.0 Hz, 4JH-H = 2.2 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2H), 4.26 – 4.18 (m, 2H), 4.06 – 
3.99 (m, 3H), 2.92 (s, 3H), 2.39 – 2.33 (m, 1H), 2.25 – 2.16 (m, 1H). 
N-[[6-fluoro-8-(methylamino)-4-[3-(methylamino)pyrrolidin-1-yl]-9H-pyrimido[4,5-b]indol-2-
yl]methyl]oxazole-4-carboxamide hydrochloride (2bc) 
Following the general procedure above: a) tert-butyl N-[1-[8-[tert-butoxycarbonyl(methyl)amino]-6-
fluoro-2-[(oxazole-4-carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-
carbamate 30 mg; b) 4 mL; c) 0.1 mL; d) 3 mg. 
White solid; yield 14%; LCMS: RT = 2.33 min, [M+H]+ 439.1; 1H NMR (500 MHz, DMSO-d6) δH 11.67 (s, 
1H), 8.69 (d, 4JH-H = 1.1 Hz, 1H), 8.56 (d, 4JH-H = 1.1 Hz, 1H), 8.52 (t, J = 5.4 Hz, 1H), 7.04 (dd, 3JH-F = 11.1 
Hz, 4JH-H = 2.2 Hz, 1H), 6.30 (dd, 3JH-F = 11.8 Hz, 4JH-H = 2.2 Hz, 1H), 5.73 (d, J = 5.0 Hz, 1H), 4.47 (d, J = 
5.5 Hz, 2H), 4.02 – 3.92 (m, 2H), 3.87 – 3.79 (m, 1H), 3.64 (dd, J = 10.7, 4.3 Hz, 1H), 3.27 – 3.23 (m, 
1H), 2.86 (d, J = 4.9 Hz, 3H), 2.28 (s, 3H), 2.07 – 2.00 (m, 1H), 1.87 – 1.80 (m, 1H). 
N-[[6-fluoro-8-(methylamino)-4-[3-(methylamino)pyrrolidin-1-yl]-9H-pyrimido[4,5-b]indol-2-
yl]methyl]oxazole-5-carboxamide hydrochloride (2bd) 
Following the general procedure above: a) tert-butyl N-[1-[8-[tert-butoxycarbonyl(methyl)amino]-6-
fluoro-2-[(oxazole-5-carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-N-methyl-
carbamate 32 mg; b) 5 mL; c) 0.1 mL; d) 7 mg. 
Beige solid; yield 32%; LCMS: RT = 2.33 min, [M+H]+ 439.4; 1H NMR (500 MHz, DMSO-d6) δH 11.59 (s, 
1H), 8.95 (t, J = 6.0 Hz, 1H), 8.59 (s, 1H), 7.85 (s, 1H), 7.03 (dd, 3JH-F = 11.1 Hz, 4JH-H = 2.2 Hz, 1H), 6.31 
(dd, 3JH-F = 12.0 Hz, 4JH-H = 2.2 Hz, 1H), 5.66 (d, J = 5.0 Hz, 1H), 4.47 (d, J = 6.0 Hz, 2H), 4.04 – 3.93 (m, 
2H), 3.87 – 3.79 (m, 1H), 3.71 (dd, J = 11.1, 4.3 Hz, 1H), 3.44 – 3.40 (m, 1H), 2.85 (d, J = 5.0 Hz, 3H), 
2.38 (s, 3H), 2.15 – 2.07 (m, 1H), 1.96 – 1.89 (m, 1H). 
N-((6-fluoro-8-(methylamino)-4-(3-(methylamino)pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indol-2-
yl)methyl)-4-methyloxazole-5-carboxamide hydrochloride (2be) 
Following the general procedure above: a) tert-butyl N-[1-[8-[tert-butoxycarbonyl(methyl)amino]-6-
fluoro-2-[[(4-methyloxazole-5-carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-4-yl]pyrrolidin-3-yl]-
N-methyl-carbamate 21 mg; b) 3 mL; c) 0.1 mL; d) 15 mg. 
Orange solid; yield 93%; LCMS: RT = 2.37 min, [M+H]+ 453.1; 1H NMR (500 MHz, DMSO-d6) δH 12.42 
(s, 1H), 9.16 – 9.00 (m, 2H), 8.87 (t, J = 7.1 Hz, 1 H), 8.47 (s, 1H), 7.07 (dd, 3JH-F = 10.7 Hz, 4JH-H = 2.2 Hz, 
1H), 6.40 (dd, 3JH-F = 11.4 Hz, 4JH-H 2.2 Hz, 1H), 4.59 (d, J = 5.9 Hz, 2H), 4.29 – 4.16 (m, 2H), 4.15 – 4.05 
(m, 1H), 4.04 – 3.97 (m, 1H), 3.97 – 3.87 (m, 1H), 2.86 (s, 3H), 2.64 (s, 3H), 2.56 – 2.51 (m, 1H), 2.38 
(s, 3H), 2.36 – 2.35 (m, 1H). 
N-[[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]oxazole-5-carboxamide hydrochloride (2cd) 
Following the general procedure above: a) tert-butyl (4-(3-(dimethylamino)pyrrolidin-1-yl)-6-fluoro-
2-((oxazole-5-carboxamido)methyl)-9H-pyrimido[4,5-b]indol-8-yl)(methyl)carbamate 17 mg; b) 1 mL; 
c) 0.1 mL; d) 7 mg. 
Yellow solid; yield 32%; LCMS: RT = 2.34 min, [M+H]+ 453.1; 1H NMR (500 MHz, DMSO-d6) δH 12.32 
(s, 1H), 10.59 (s, 1H), 9.19 (t, J = 6.0 Hz, 1H), 8.60 (s, 1H), 7.88 (s, 1H), 7.07 (dd, 3JH-F = 10.7 Hz, 4JH-H = 
2.2 Hz, 1H), 6.40 (dd, 3JH-F = 11.9 Hz, 4JH-H = 2.2 Hz, 1H), 4.61 (d, J = 6.1 Hz, 2H), 4.27 – 4.11 (m, 3H), 
4.13 – 3.98 (m, 2H), 2.86 (s, 3H), 2.84 (d, J = 11.6 Hz, 6H), 2.55 – 2.52 (m, 1H), 2.35 – 2.25 (m, 1H). 
N-[[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]-4-methyl-oxazole-5-carboxamide hydrochloride (2ce) 
Following the general procedure above: a) tert-butyl N-[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-
fluoro-2-[[(4-methyloxazole-5-carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-
carbamate 20 mg; b) 1 mL; c) 0.1 mL; d) 14 mg. 
Orange solid; yield 85%; LCMS: RT = 2.46 min, [M+H]+ 467.1; 1H NMR (500 MHz, DMSO-d6) δH 12.40 
(s, 1H), 10.72 (s, 1H), 8.86 (s, 1H), 8.46 (s, 1H), 7.06 (d, 3JH-F = 10.7 Hz, 1H), 6.40 (d, 3JH-F = 11.7 Hz, 1H), 
4.59 (d, J = 5.8 Hz, 2H), 4.29 – 4.13 (m, 3H), 4.12 – 3.96 (m, 2H), 2.88 – 2.78 (m, 9H), 2.64 – 2.60 (m, 
1H), 2.37 (s, 3H), 2.37 – 2.33 (m, 1H). 
N-[[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]-2-methyl-oxazole-5-carboxamide hydrochloride (2cf) 
Following the general procedure above: a) tert-butyl N-[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-
fluoro-2-[[(2-methyloxazole-5-carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-
carbamate 42 mg; b) 2 mL; c) 0.2 mL; d) 7 mg. 
Beige solid; yield 32%; LCMS: RT = 2.35 min, [M+H]+ 467.2; 1H NMR (500 MHz, DMSO-d6) δH 12.47 (s, 
1H), 10.41 (s, 1H), 9.11 (t, J = 6.0 Hz, 1H), 7.73 (s, 1H), 7.09 (dd, 3JH-F = 10.7 Hz, 4JH-H = 2.2 Hz, 1H), 6.42 
(dd, 3JH-F = 12.0 Hz, 4JH-H = 2.2 Hz, 1H), 4.62 (d, J = 6.0 Hz, 2H), 4.29 – 3.98 (m, 5H), 2.89 – 2.82 (m, 9H), 
2.75 (t, J = 5.1 Hz, 1H), 2.47 – 2.43 (m, 3H), 2.34 – 2.28 (m, 1H). 
N-[[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]furan-2-carboxamide (2cg) 
Following the general procedure above: a) tert-butyl N-[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-
fluoro-2-[(furan-2-carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 28 mg; 
b) 2 mL; c) 0.2 mL; d) 11 mg. 
Yellow solid; yield 48%; LCMS: RT = 2.80 min, [M+H]+ 452.3; 1H NMR (500 MHz, DMSO-d6) δH 12.45 
(s, 1H), 11.38 (s, 1H), 8.89 (t, J = 5.9 Hz, 1H), 7.92 – 7.88 (m, 1H), 7.25 – 7.20 (m, 1H), 7.05 (dd, 3JH-F = 
11.0 Hz, 4JH-H = 2.2 Hz, 1H), 6.70 – 6.65 (m, 1H), 6.39 (dd, 3JH-F = 11.9 Hz, 4JH-H = 2.1 Hz, 1H), 4.62 – 4.57 
(m, 2H), 4.23 – 4.16 (m, 3H), 4.10 – 3.96 (m, 2H), 2.86 (s, 3H), 2.81 (dd, J = 18.3, 4.7 Hz, 6H), 2.47 – 
2.43 (m, 1H), 2.41 – 2.32 (m, 1H).  
 
N-[[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]-1H-pyrrolo[2,3-b]pyridine-6-carboxamide hydrochloride (2ch) 
Following the general procedure above: a) tert-butyl N-[4-[3-(dimethylamino)pyrrolidin-1-yl]-6-
fluoro-2-[(1H-pyrrolo[2,3-b]pyridine-6-carbonylamino)methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-
methyl-carbamate 11 mg; b) 1 mL; c) 0.1 mL; d) 9 mg. 
Yellow solid; yield 98%; LCMS: RT = 3.21 min, [M+H]+ 502.3; 1H NMR (500 MHz, DMSO-d6) δH 12.31 
(s, 1H), 11.91 (s, 1H), 10.63 (s, 1H), 9.06 (t, J = 5.7 Hz, 1H), 8.14 (d, J = 8.1 Hz, 1H), 7.86 (d, J = 8.1 Hz, 
1H), 7.75 – 7.71 (m, 1H), 7.08 (dd, 3JH-F = 10.9 Hz, 4JH-H = 2.2 Hz, 1H), 6.60 (dd, J = 3.4, 1.8 Hz, 1H), 6.41 
(dd, 3JH-F = 12.0 Hz, 4JH-H = 2.2 Hz, 1H), 4.75 (d, J = 5.7 Hz, 2H), 4.29 – 4.15 (m, 3H), 4.14 – 4.06 (m, 1H), 
4.05 – 3.98 (m, 1H), 2.87 (s, 3H), 2.87 – 2.73 (m, 6H), 2.47 – 2.45 (m, 1H), 2.36 – 2.28 (m, 1H). 
N-[[4-[3-(aminomethyl)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]oxazole-5-carboxamide hydrochloride (2dd) 
Following the general procedure above: a) tert-butyl N-[4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-2-[(oxazole-5-carbonylamino)methyl]-9H-
pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 47 mg; b) 2 mL; c) 0.2 mL; d) 7 mg. 
Yellow solid; yield 32%; LCMS: RT = 2.13 min, [M+H]+ 439.1; 1H NMR (500 MHz, CD3OD) δH 8.32 (s, 
1H), 7.75 (s, 1H), 7.13 (dd, 3JH-F = 10.7 Hz, 4JH-H = 2.2 Hz, 1H), 6.43 (dd, 3JH-F = 10.7 Hz, 4JH-H = 2.2 Hz, 
1H), 4.68 (s, 2H), 4.28 – 4.19 (m, 1H), 4.15 – 4.05 (m, 2H), 3.88 – 3.79 (m, 1H), 3.15 – 3.08 (m, 2H), 
3.05 – 2.99 (m, 1H), 2.88 (s, 3H), 2.70 – 2.62 (m, 1H), 2.35 – 2.27 (m, 1H), 1.90 – 1.83 (m, 1H). 
N-[[4-[3-(aminomethyl)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]-4-methyl-oxazole-5-carboxamide hydrochloride (2de) 
Following the general procedure above: a) tert-butyl N-[4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-2-[[(4-methyloxazole-5-
carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 29 mg; b) 2 mL; c) 0.2 
mL; d) 21 mg. 
Yellow solid; yield 99%; LCMS: RT = 2.26 min, [M+H]+ 453.1; 1H NMR (500 MHz, CD3OD) δH 8.19 (s, 
1H), 7.14 (d, 3JH-F = 10.5 Hz, 1H), 6.44 (d, 3JH-F = 10.5 Hz, 1H), 4.65 (s, 2H), 4.33 – 4.19 (m, 1H), 4.19 – 
4.04 (m, 2H), 3.92 – 3.79 (m, 1H), 3.09 – 2.96 (m, 2H), 2.88 (s, 3H), 2.74 – 2.64 (m, 1H), 2.38 (s, 3H), 
2.35 – 2.28 (m, 1H), 1.96 – 1.84 (m, 1H). 
N-[[4-[3-(aminomethyl)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-2-
yl]methyl]-2-methyl-oxazole-5-carboxamide hydrochloride (2df) 
Following the general procedure above: a) tert-butyl N-[4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-6-fluoro-2-[[(2-methyloxazole-5-
carbonyl)amino]methyl]-9H-pyrimido[4,5-b]indol-8-yl]-N-methyl-carbamate 24 mg; b) 2 mL; c) 0.2 
mL; d) 14 mg. 
Yellow solid; yield 84%; LCMS: RT = 2.30 min, [M+H]+ 453.3; 1H NMR (500 MHz, CD3OD) δH 7.61 (s, 
1H), 7.11 (dd, 3JH-F = 11.0 Hz, 4JH-H = 2.2 Hz, 1H), 6.41 (dd, 3JH-F = 11.0 Hz, 4JH-H = 2.2 Hz, 1H), 4.65 (s, 
2H), 4.28 – 4.19 (m, 1H), 4.18 – 4.01 (m, 2H), 3.89 – 3.77 (m, 1H), 3.14 – 3.09 (m, 2H), 3.06 – 2.99 (m, 
2H), 2.87 (s, 3H), 2.70 – 2.60 (m, 1H), 2.47 (s, 3H), 2.36 – 2.26 (m, 1H), 1.95 – 1.80 (m, 1H). 
methyl 6-[[4-[3-(aminomethyl)pyrrolidin-1-yl]-6-fluoro-8-(methylamino)-9H-pyrimido[4,5-b]indol-
2-yl]methylcarbamoyl]pyridine-2-carboxylate hydrochloride (2di) 
Following the general procedure above: a) methyl 6-[[4-[3-[(tert-
butoxycarbonylamino)methyl]pyrrolidin-1-yl]-8-[tert-butoxycarbonyl(methyl)amino]-6-fluoro-9H-
pyrimido[4,5-b]indol-2-yl]methylcarbamoyl]pyridine-2-carboxylate 34 mg; b) 1 mL; c) 0.1 mL; d) 21 
mg. 
Orange solid; yield 86%; LCMS: RT = 2.65 mins, [M+H]+ 507.1; 1H NMR (500 MHz, CD3OD) δH 8.29 – 
8.23 (m, 2H), 8.12 (t, J = 7.9 Hz, 1H), 7.09 (dd, 3JH-F = 10.4 Hz, 4JH-H = 2.2 Hz, 1H), 6.38 (dd, 3JH-F = 11.7 
Hz, 4JH-H = 2.2 Hz, 1H), 4.77 – 4.76 (m, 2H), 4.31 – 4.21 (m, 1H), 4.19 – 4.04 (m, 2H), 3.96 (s, 3H), 3.89 
– 3.81 (m, 1H), 3.16 – 3.11 (m, 1H), 3.06 – 2.99 (m, 1H), 2.86 (s, 3H), 2.70 – 2.61 (m, 1H), 2.35 – 2.27 
(m, 1H), 1.93 – 1.81 (m, 1H). 
